Yu, Pengfei
Chen, Ping
Wu, Min
Ding, Guangyu
Bao, Hua
Du, Yian
Xu, Zhiyuan
Yang, Litao
Fang, Jingquan
Huang, Xingmao
Lai, Qian
Wei, Jia
Yan, Junrong
Yang, Shanshan
He, Peng
Wu, Xue
Shao, Yang
Su, Dan
Cheng, Xiangdong
Funding for this research was provided by:
The National Key Research and Development Program of China (No.2021YFA0910104)
Article History
Received: 18 April 2023
Accepted: 29 May 2024
First Online: 7 June 2024
Declarations
:
: The study was approved by the Institutional Ethics Committee of Zhejiang Cancer Hospital (No. IRB-2021–295) and performed in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent to participate. This study was registered on ClinicalTrials.gov under the identifier NCT05269056 on March 7, 2022.
: All participants provided written informed consent to publish data collected in the study.
: Authors M.W., H.B., J.Y., S.Y., P.H., X.W., and Y.S. are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare that they do not have any competing interests.